SeaStar Medical Hit With Nasdaq Deficiency Notice on $2.5M Equity Rule
ICU sits 20% above its 52-week low of $0.761.
Summary
SeaStar received a Nasdaq notice that it fails the $2.5 million stockholders' equity requirement, with until January 4, 2027 to submit a compliance plan. It follows the going-concern warning and $3.989 million cash balance disclosed in the November 12 10-Q.
Key Events · Legal and Risk Events · ICU
-
Nasdaq Equity Deficiency Notice
On November 20, 2026, Nasdaq's Listing Qualifications Staff notified SeaStar that it is not in compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders' equity for Capital Market companies with under $35 million in listed securities and under $500,000 of annual net income.
-
45-Day Plan Deadline
SeaStar has until January 4, 2027 to submit a compliance plan; if Nasdaq accepts it, the Staff has discretion to grant a 180-calendar-day extension to regain compliance.
-
Delisting Risk If Plan Rejected
A rejected plan would trigger written notice that the common stock is subject to delisting, after which the company could appeal to a Nasdaq Hearing Panel. The notice has no immediate effect on listing.
-
Tied to Going-Concern Warning
The deficiency follows the November 12, 2026 10-Q, which reported cash of $3.989 million and management's substantial doubt about continuing as a going concern — the equity shortfall is the same balance-sheet problem surfacing at the listing level.
Analysis · ICU · Industrial Applications And Services
Nasdaq says SeaStar falls short of the $2.5 million stockholders' equity minimum required of Capital Market companies with under $35 million in listed securities and under $500,000 of annual net income. The company has until January 4, 2027 to file a plan to regain compliance; if Nasdaq accepts it, the Staff has discretion to allow up to 180 additional days. This lands four days after the Q3 10-Q disclosed substantial doubt about continuing as a going concern and cash of $3.989 million, so the equity shortfall is a direct symptom of the same balance-sheet problem. The notice does not suspend trading today, but a rejected plan leads to a delisting determination and an appeal process — a real risk for a stock already trading near $0.91.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICU was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.76 to $5.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.